| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

13 December 2021

ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

22 November 2021

ORYZON announces new Global Chief Business Officer and expansion of US corporate activities

17 November 2021

ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia

15 November 2021

ORYZON publishes paper in ACS Pharmacology & Translational Science supporting best-in-class performance of iadademstat in Oncology

11-14 December 2021

63th American Society of Hematology 2021 Congress (ASH-2021)

Atlanta

GA

United States

30 November - 2 December 2021

Evercore ISI 4th Annual HealthCONx Conference 2021

16-19 November 2021

Jefferies London Healthcare Conference 2021

9 November 2021

ORYZON to present new clinical data and corporate updates at international conferences in November and December

28 October 2021

ORYZON reports results and corporate update for quarter ended September 30, 2021

18 October 2021

ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

Pagination

First page «
Previous page ‹
Page 19
Page 20
Page 21
Page 22
Current page 23
Page 24
Page 25
Page 26
Page 27
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel